UnlockMajor Shareholder Announcement
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Genmab (0MGB)
1,600.50
-10.25(-0.64%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,595.50
1,611.00
52 wk Range
1,563.00
2,292.00
0MGB Scorecard
Full Analysis
Management has been aggressively buying back shares
Genmab stock price live, this page displays CSE GMAB stock exchange data. View the GMAB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Genmab real time stock price chart below.
What Is the Genmab Stock Price Today?
The Genmab stock price today is 1,600.50.
What Is the Stock Symbol for Genmab?
The stock symbol for Genmab is "GMAB."
What Stock Exchange Does Genmab Trade On?
Genmab is listed and trades on the Copenhagen stock exchange.
Is Genmab a Good Stock to Buy?
Determining whether Genmab—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GMAB quote. (ISIN: DK0010272202)
What Is the Genmab Stock Price Today?
The Genmab stock price today is 1,600.50.
What Is the Stock Symbol for Genmab?
The stock symbol for Genmab is "GMAB."
What Stock Exchange Does Genmab Trade On?
Genmab is listed and trades on the Copenhagen stock exchange.
Is Genmab a Good Stock to Buy?
Determining whether Genmab—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GMAB quote. (ISIN: DK0010272202)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,595.501,611.00
52 wk Range
1,563.002,292.00
0MGB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
2,408.50
Upside
+50.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Genmab Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Compare 0MGB to Peers and Sector
Metrics to compare | 0MGB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0MGBPeersSector | |
|---|---|---|---|---|
P/E Ratio | 18.4x | −4.5x | −0.6x | |
PEG Ratio | 0.92 | −0.06 | 0.00 | |
Price/Book | 3.3x | 4.8x | 2.6x | |
Price / LTM Sales | 5.4x | 8.2x | 3.2x | |
Upside (Analyst Target) | - | 45.7% | 46.9% | |
Fair Value Upside | Unlock | −5.1% | 7.9% | Unlock |
People Also Watch
FAQ
What Is the Genmab (0MGB) Stock Price Today?
The Genmab stock price today is 1,600.50
What Stock Exchange Does Genmab Trade On?
Genmab is listed and trades on the London stock exchange.
What Is the Stock Symbol for Genmab?
The stock symbol for Genmab is "0MGB."
What Is the Genmab Market Cap?
As of today, Genmab market cap is 101.80B.
What is Genmab Earnings Per Share?
The Genmab EPS is 85.11.
What Is the Next Genmab Earnings Date?
Genmab will release its next earnings report on 05 Nov 2024.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.